New Drug Slashed Deaths Among Patients with Severe Covid, Maker Claims
April 11, 2022
(New York Times) – An experimental drug halved the death rate among critically ill Covid patients who were receiving supplemental oxygen and were at high risk for serious lung disease and death, the drug’s developer announced on Monday. There is a pressing need for new treatments for critically ill patients. Drugs like Paxlovid, made by Pfizer, are aimed primarily at patients who have mild or moderate disease. Other treatments administered to hospitalized patients in serious condition have shown limited effectiveness. (Read More)